These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 31874120

  • 1. Idiopathic pulmonary fibrosis lung transplant recipients are at increased risk for EBV-associated posttransplant lymphoproliferative disorder and worse survival.
    Iasella CJ, Winters SA, Kois A, Cho J, Hannan SJ, Koshy R, Moore CA, Ensor CR, Lendermon EA, Morrell MR, Pilewski JM, Sanchez PG, Kass DJ, Alder JK, Nouraie SM, McDyer JF.
    Am J Transplant; 2020 May; 20(5):1439-1446. PubMed ID: 31874120
    [Abstract] [Full Text] [Related]

  • 2. Posttransplant Lymphoproliferative Disorders in Epstein-Barr Virus Donor Positive/Recipient Negative Lung Transplant Recipients.
    Courtwright AM, Burkett P, Divo M, Keller S, Rosas IO, Trindade A, Mody GN, Singh SK, El-Chemaly S, Camp PC, Goldberg HJ, Mallidi HR.
    Ann Thorac Surg; 2018 Feb; 105(2):441-447. PubMed ID: 29223419
    [Abstract] [Full Text] [Related]

  • 3. Evidence of Epstein-Barr virus heterogeneous gene expression in adult lung transplant recipients with posttransplant lymphoproliferative disorder.
    Zaffiri L, Frankel C, Bush EJ, Neely ML, Pavlisko EN, Mokrova IL, Luftig MA, Palmer SM.
    J Med Virol; 2021 Aug; 93(8):5040-5047. PubMed ID: 33704812
    [Abstract] [Full Text] [Related]

  • 4. Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients.
    Sampaio MS, Cho YW, Shah T, Bunnapradist S, Hutchinson IV.
    Transplantation; 2012 Jan 15; 93(1):73-81. PubMed ID: 22129761
    [Abstract] [Full Text] [Related]

  • 5. Epstein-Barr virus primary mismatching and HLA matching: key risk factors for post lung transplant lymphoproliferative disease.
    Wong JY, Tait B, Levvey B, Griffiths A, Esmore DS, Snell GI, Williams TJ, Kotsimbos TC.
    Transplantation; 2004 Jul 27; 78(2):205-10. PubMed ID: 15280679
    [Abstract] [Full Text] [Related]

  • 6. Incidence, Risk Factors, Clinical Management, and Outcomes of Posttransplant Lymphoproliferative Disorder in Kidney Transplant Recipients.
    Liu M, Husain S, Famure O, Li Y, Kim SJ.
    Prog Transplant; 2019 Jun 27; 29(2):185-193. PubMed ID: 30845885
    [Abstract] [Full Text] [Related]

  • 7. Incidence and outcome of post-transplant lymphoproliferative disorders in lung transplant patients: Analysis of ISHLT Registry.
    Zaffiri L, Long A, Neely ML, Cherikh WS, Chambers DC, Snyder LD.
    J Heart Lung Transplant; 2020 Oct 27; 39(10):1089-1099. PubMed ID: 32654913
    [Abstract] [Full Text] [Related]

  • 8. Epstein-Barr Virus DNAemia and post-transplant lymphoproliferative disorder in pediatric solid organ transplant recipients.
    Chang YC, Young RR, Mavis AM, Chambers ET, Kirmani S, Kelly MS, Kalu IC, Smith MJ, Lugo DJ.
    PLoS One; 2022 Oct 27; 17(10):e0269766. PubMed ID: 36256635
    [Abstract] [Full Text] [Related]

  • 9. The Changing Epidemiology of Posttransplant Lymphoproliferative Disorder in Adult Solid Organ Transplant Recipients Over 30 Years: A Single-center Experience.
    Peters AC, Akinwumi MS, Cervera C, Mabilangan C, Ghosh S, Lai R, Iafolla M, Doucette K, Preiksaitis JK.
    Transplantation; 2018 Sep 27; 102(9):1553-1562. PubMed ID: 29485513
    [Abstract] [Full Text] [Related]

  • 10. Transplantation for congenital heart disease is associated with an increased risk of Epstein-Barr virus-related post-transplant lymphoproliferative disorder in children.
    Offor UT, Bacon CM, Roberts J, Powell J, Brodlie M, Wood K, Windebank KP, Flett J, Hewitt T, Rand V, Hasan A, Parry G, Gennery AR, Reinhardt Z, Bomken S.
    J Heart Lung Transplant; 2021 Jan 27; 40(1):24-32. PubMed ID: 33339556
    [Abstract] [Full Text] [Related]

  • 11. Determination of risk factors for Epstein-Barr virus-associated posttransplant lymphoproliferative disorder in pediatric liver transplant recipients using objective case ascertainment.
    Guthery SL, Heubi JE, Bucuvalas JC, Gross TG, Ryckman FC, Alonso MH, Balistreri WF, Hornung RW.
    Transplantation; 2003 Apr 15; 75(7):987-93. PubMed ID: 12698085
    [Abstract] [Full Text] [Related]

  • 12. Adolescents are more likely to develop posttransplant lymphoproliferative disorder after primary Epstein-Barr virus infection than younger renal transplant recipients.
    Smith JM, Corey L, Healey PJ, Davis CL, McDonald RA.
    Transplantation; 2007 Jun 15; 83(11):1423-8. PubMed ID: 17565314
    [Abstract] [Full Text] [Related]

  • 13. Association of antiviral prophylaxis and rituximab use with posttransplant lymphoproliferative disorders (PTLDs): A nationwide cohort study.
    Walti LN, Mugglin C, Sidler D, Mombelli M, Manuel O, Hirsch HH, Khanna N, Mueller N, Berger C, Boggian K, Garzoni C, Neofytos D, van Delden C, Hirzel C, Swiss Transplant Cohort Study (STCS)Department of Infectious Diseases, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland..
    Am J Transplant; 2021 Jul 15; 21(7):2532-2542. PubMed ID: 33289340
    [Abstract] [Full Text] [Related]

  • 14. Increased risk of PTLD in lung transplant recipients with cystic fibrosis.
    Lowery EM, Adams W, Grim SA, Clark NM, Edwards L, Layden JE.
    J Cyst Fibros; 2017 Nov 15; 16(6):727-734. PubMed ID: 28456611
    [Abstract] [Full Text] [Related]

  • 15. Post-transplant lymphoproliferative disorders, Epstein-Barr virus infection, and disease in solid organ transplantation: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.
    Allen UD, Preiksaitis JK, AST Infectious Diseases Community of Practice.
    Clin Transplant; 2019 Sep 15; 33(9):e13652. PubMed ID: 31230381
    [Abstract] [Full Text] [Related]

  • 16. Post-transplant lymphoproliferative disease in lung transplantation: A nested case-control study.
    Leyssens A, Dierickx D, Verbeken EK, Tousseyn T, Verleden SE, Vanaudenaerde BM, Dupont LJ, Yserbyt J, Verleden GM, Van Raemdonck DE, Vos R.
    Clin Transplant; 2017 Jul 15; 31(7):. PubMed ID: 28383790
    [Abstract] [Full Text] [Related]

  • 17. Combined assessment of Epstein-Barr virus viral capsid antigen and Epstein-Barr virus nuclear antigen-1 serology for post-transplant lymphoproliferative disorder risk stratification in adult solid organ transplant recipients.
    Heldman MR, Edlefsen KL, Pepper G, Kapnadak SG, Rakita RM, Fisher CE, Limaye AP.
    Transpl Infect Dis; 2022 Dec 15; 24(6):e13933. PubMed ID: 36000190
    [Abstract] [Full Text] [Related]

  • 18. Roles of Epstein-Barr virus viral load monitoring in the prediction of posttransplant lymphoproliferative disorder in pediatric liver transplantation.
    Chen HS, Ho MC, Hu RH, Wu JF, Chen HL, Ni YH, Hsu HY, Jeng YM, Chang MH.
    J Formos Med Assoc; 2019 Sep 15; 118(9):1362-1368. PubMed ID: 30612881
    [Abstract] [Full Text] [Related]

  • 19. Epstein-Barr Virus Predicts Malignancy After Pediatric Heart Transplant, Induction Therapy and Tacrolimus Don't.
    Giuliano K, Canner JK, Scully BB, Clarke N, Fraser CD, Ravekes W, Mettler B, Jacobs ML, Sen DG.
    Ann Thorac Surg; 2022 Nov 15; 114(5):1794-1802. PubMed ID: 34563503
    [Abstract] [Full Text] [Related]

  • 20. Risk factors and clinical outcomes of Epstein-Barr virus DNAemia and post-transplant lymphoproliferative disorders after haploidentical and matched-sibling PBSCT in patients with hematologic malignancies.
    Gao XN, Lin J, Wang LJ, Li F, Li HH, Wang SH, Huang WR, Gao CJ, Yu L, Liu DH.
    Ann Hematol; 2019 Sep 15; 98(9):2163-2177. PubMed ID: 31243569
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.